France Italy Russia Spain Benelux Nordic Rest of Europe Asia-Pacific China Japan South Korea India ANZ ASEAN Rest of Asia-Pacific Latin America Brazil Mexico Argentina Colombia Rest of Latin America Middle East & Africa Saudi Arabia UAE South Africa Israel Egypt Rest of MEA Competitive Landscape The senolytic drugs market is quite new and competitive, with various biotechnology firms and research institutions aiming to develop innovative therapies
The mechanism is still active in leaner individuals just with proportionally smaller output
Clinical trials demonstrate that cumulative weight loss increases across the dose range, but individual response varies based on metabolism, genetics, and gastrointestinal tolerance
Safety considerations Reconstituting and handling peptides at home carries inherent responsibilities
References Nieto-Martnez R et al (2017) Are eating disorders risk factors for type 2 diabetes
After at least 4 weeks, the dose can be increased to 1 mg weekly and, if necessary, to a maximum of 2 mg weekly for additional glycaemic control